Project description
Introducing a novel approach to combat antimicrobial-resistant pathogens
It is estimated that antimicrobial resistance of pathogens could become the major cause of death by 2050. Many gram-negative bacteria are especially life-threatening due to their antibiotic resistance and high presence in hospital intensive care units. The EU-funded HAIKU project aims to confirm the preclinical development process and review market conditions for RA-01, a novel drug that prevents internal bacterial infection by removing specific antibodies. This will lead to the next stage of RA-01 clinical trials, licensing and market delivery. The project will enable the prevention of infectious diseases in intensive care units, thus saving lives, reducing length of hospital stays and significantly cutting healthcare expenses.
Objective
Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The
most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics.
We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at
ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug
allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR).
RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150
reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs.
Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the
removing of specific antibodies as a preventive and curative method for infectious diseases.
The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for
prolonged stays: >4 million patients.
RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies.
Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by
infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to
pharma companies, to finalise their development and bring them to the market
By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000
(complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10%
discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly
created jobs.
Fields of science
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicinecritical care medicine
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
08907 HOSPITALET DE LLOBREGAT
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.